Analysis of Cox 2 Inhibitors Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Expanding at a CAGR of 12.5%, the global COX2 inhibitor market is projected to increase from a valuation of US$ 109.91 billion in 2024 to US$ 355.39 billion by 2034.
A category of nonsteroidal anti-inflammatory medicines (NSAIDs) known as cyclooxygenase 2 inhibitors functions by lowering prostaglandin synthesis. Prostaglandins are molecules that increase temperature, inflammation, and pain. COX-2 inhibitors, also known as cyclooxygenase 2 inhibitors, are used to treat inflammation, mild to moderate fever, and discomfort.
According to Fact.MR, the market for cyclooxygenase 2 inhibitors is approximated to expand going forward.
One of the main factors propelling the growth of the cyclooxygenase 2 inhibitor market is the rise in the incidence of inflammatory and painful diseases, such as rheumatoid arthritis and osteoarthritis worldwide. The market is growing as a consequence of the rise in mergers and acquisitions between producers and research institutions to offer patients effective medical treatment and produce substantial profits from their sales choices.
The market will grow thanks to the widespread usage of cyclooxygenase 2 inhibitors, such as CeleCOXib, which are just as efficient in reducing pain and inflammation as other NSAIDs, such as ibuprofen, diclofenac, and naproxen. Several governmental and commercial entities are investing more in the creation of innovative therapies and interventions that expand the market for cyclooxygenase 2 inhibitors.
The market for cyclooxygenase 2 inhibitors is favorably impacted by the growing need for efficient treatments, technological advancements, a rise in healthcare spending, a sizable patient population, and advanced medical technology.
| Report Attribute | Detail |
|---|---|
| COX2 Inhibitor Market Size (2024E) | US$ 109.91 Billion |
| Forecasted Market Value (2034F) | US$ 355.39 Billion |
| Global Market Growth Rate (2024 to 2034) | 12.5% CAGR |
| East Asia Market Value (2034F) | US$ 66.81 Billion |
| North America Market Growth Rate (2034F) | 15.2% |
| Drug Stores Segment Value (2034F) | US$ 71.69 Billion |
| Japan Market Value (2034F) | US$ 10.42 Billion |
| Key Companies Profiled | Pfizer; Merck; Novartis; Bayer; Teva Pharmaceutical; Aurobindo Pharma; Lupin Pharmaceuticals; Almirall; Mylan (Now part of Viatris) |
COX 2 Inhibitors are a type of non-steroidal anti-inflammatory drugs. These drugs are responsible for decreasing the production of prostaglandins.
These drugs also reduce the production of chemicals that play an important role in promoting fever, inflammatory pain, and others. Cyclooxygenase (COX) is an enzyme, which is responsible for producing prostaglandins. The cyclooxygenase enzymes are of two types- COX 1 and COX 2. COX2 inhibitors, reduce the production of prostaglandins and, hence, reduce inflammatory pain, fever, and other issues.
There are some safety issues, associated with COX 2 inhibitors, hence, they have been taken off from the United States market. In addition, several products have been recalled in the market. For example- Vioxx, which is a COX 2 inhibitor, was recalled worldwide in 2004 as it caused cardiovascular diseases such as heart attacks and heart strokes.
Bextra, which is another COX 2 inhibitor, was taken off from several markets in Europe and the United States in April 2005 due to cardiovascular risks and life-threatening skin reactions. There are several other products, such as Prexige, which were withdrawn from most of the world’s market because of the severe liver damage caused by this drug. There are several controversies ongoing, which are criticizing the use of COX2 inhibitors.
CeleCOXib is the only COX-2 inhibitor, which is currently available in the United States. There is a new approach to manufacturing natural COX 2 inhibitors, which is being adopted by the company, Sabinsa. Manufacturers of natural COX 2 inhibitors have very few side effects and are highly adopted by more people.
The high adoption rate of COX2 inhibitors, such as aspirin painkillers, is one of the major factors, driving the growth of the COX2 inhibitor market. The increasing prevalence of chronic diseases, such as rheumatoid arthritis, osteoarthritis, and other diseases, is expected to increase the growth of the COX2 inhibitor market. Increasing awareness of physical activities leads to sports injury, which is also driving global market growth.
The COX 2 inhibitors have several safety issues; hence, some of the COX 2 inhibitors have been withdrawn from the market. For example- ArCOXia is a COX 2 inhibitor, which is present in several countries but not in the United States Dynastat is another COX 2 inhibitor, which is a form of injectable medicine.
The safety issues, associated with COX 2 inhibitors, restrain the growth of the COX 2 inhibitor market. Intake of COX 2 inhibitors, also causes gastrointestinal problems for the people, which decreases the demand for these inhibitors and, hence, hamper the growth of the overall market. Other side effects, such as headache, migraine, and nausea, also decrease the demand for COX 2 inhibitors.
How is the COX 2 inhibitor market projected to grow during the forecast period?
COX 2 inhibitor market is analyzed to grow at a CAGR of 12.5% during the forecast period.
Why COX 2 inhibitor market have high growth potential?
The widespread use of COX 2 inhibitors, such as the popular pain reliever aspirin is a key driver behind the expansion.
Where will manufacturers find most opportunities in the COX2 inhibitor industry?
North America is analyzed to be the more lucrative region for the growth of the COX2 inhibitor industry.
Table 1: Global Market US$ Mn Forecast by Region
Table 2: Global Market US$ Mn Forecast by Product Type
Table 3: Global Market US$ Mn Forecast by Indication
Table 4: Global Market US$ Mn Forecast by Distribution Channels
Table 5: North America Market US$ Mn Forecast by Country
Table 6: North America Market US$ Mn Forecast by Product Type
Table 7: North America Market US$ Mn Forecast by Indication
Table 8: North America Market US$ Mn Forecast by Distribution Channels
Table 9: Latin America Market US$ Mn Forecast by Country
Table 10: Latin America Market US$ Mn Forecast by Product Type
Table 11: Latin America Market US$ Mn Forecast by Indication
Table 12: Latin America Market US$ Mn Forecast by Distribution Channels
Table 13: Western Europe Market US$ Mn Forecast by Country
Table 14: Western Europe Market US$ Mn Forecast by Product Type
Table 15: Western Europe Market US$ Mn Forecast by Indication
Table 16: Western Europe Market US$ Mn Forecast by Distribution Channels
Table 17: Eastern Europe Market US$ Mn Forecast by Country
Table 18: Eastern Europe Market US$ Mn Forecast by Product Type
Table 19: Eastern Europe Market US$ Mn Forecast by Indication
Table 20: Eastern Europe Market US$ Mn Forecast by Distribution Channels
Table 21: Asia Pacific Market US$ Mn Forecast by Country
Table 22: Asia Pacific Market US$ Mn Forecast by Product Type
Table 23: Asia Pacific Market US$ Mn Forecast by Indication
Table 24: Asia Pacific Market US$ Mn Forecast by Distribution Channels
Table 25: East Asia Market US$ Mn Forecast by Country
Table 26: East Asia Market US$ Mn Forecast by Product Type
Table 27: East Asia Market US$ Mn Forecast by Indication
Table 28: East Asia Market US$ Mn Forecast by Distribution Channels
Table 29: MEA Market US$ Mn Forecast by Country
Table 30: MEA Market US$ Mn Forecast by Product Type
Table 31: MEA Market US$ Mn Forecast by Indication
Table 32: MEA Market US$ Mn Forecast by Distribution Channels
Figure 1: Global Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Product Type
Figure 2: Global Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Indication
Figure 3: Global Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Distribution Channels
Figure 4: Global Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Region
Figure 5: North America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Product Type
Figure 6: North America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Indication
Figure 7: North America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Distribution Channels
Figure 8: North America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 9: Latin America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Product Type
Figure 10: Latin America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Indication
Figure 11: Latin America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Distribution Channels
Figure 12: Latin America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 13: Western Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Product Type
Figure 14: Western Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Indication
Figure 15: Western Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Distribution Channels
Figure 16: Western Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 17: Eastern Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Product Type
Figure 18: Eastern Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Indication
Figure 19: Eastern Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Distribution Channels
Figure 20: Eastern Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 21: Asia Pacific Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Product Type
Figure 22: Asia Pacific Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Indication
Figure 23: Asia Pacific Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Distribution Channels
Figure 24: Asia Pacific Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 25: East Asia Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Product Type
Figure 26: East Asia Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Indication
Figure 27: East Asia Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Distribution Channels
Figure 28: East Asia Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 29: MEA Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Product Type
Figure 30: MEA Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Indication
Figure 31: MEA Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Distribution Channels
Figure 32: MEA Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
COX 2 Inhibitor Market